ISSUE #3 June 11, 2025
∎ Celltrion’s Remsima SC hits fivefold growth in Europe (The Korea Herald)
∎ Korean biotech firms eye share of expanding gene therapy market (AJU PRESS)
∎ Samyang Holdings to spin off biopharm unit (The Korea Herald)
∎ HLB’s liver cancer drug extends survival in phase 3 China study (KBR)
∎ Daewoong’s Nabota Debuts in Qatar Market (BusinessKorea)
∎ Milestone partnership highlighting Korea’s expanding influence in global biotech innovation (BioSpectrum Asia)
∎ D&D Pharmatech finalizes U.S. Phase 2 clinical trial of MASH treatment candidate 'DD01' with 'database lock' completion (THE BIO)
∎ Lunit Launches Enhanced Lunit INSIGHT CXR4, Secures CE MDR Certification for Expanded AI Capabilities (THE BIO)
∎ LaMeditech secures supply agreement with Japan’s GUNZE MEDICAL for ‘CAREVEAM’ device (THE BIO)
∎ Spine Robot Wars: Curexo Rises as Global Giants Fall (PharmEdaily)
BIO USA 2025 is just around the corner!
Korea Pavilion is ready — are you joining us in Boston?
📰
Join our press list
Get KoreaBIO updates
& media resources
💬
Share Your thoughts!
How was your letter today?
✉️
Korean Newsletter
Daily biotech news from Korea and around the world
— in Korean
Explore More
KoreaBIO (Korea Biotechnology Industry Organization)
700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
+82-31-628-0037
수신거부 Unsubscribe